Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Chappell

Showing results (341-350 of 360) with videos related to

Pageof 36
Sort By:
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Science Translational Medicine|September 13, 2021
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxelChristina M Scribano, Jun Wan, Karla Esbona, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 17, 2025
Comparison of sample characteristics of Wisconsin Alzheimer's Disease Research Center participants with the Wisconsin state population-An evaluation of the recruitment effortYue Ma, Maria C Mora Pinzon, William R Buckingham, et al.
Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Science (New York, N.Y.)|January 8, 2021
A broadly protective antibody that targets the flavivirus NS1 proteinNaphak Modhiran, Hao Song, Lidong Liu, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|June 25, 2019
FLASHForward: plasma wakefield accelerator science for high-average-power applicationsR D'Arcy, A Aschikhin, S Bohlen, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
Nature Genetics|February 13, 1999
An encyclopedia of mouse genesM Marra, L Hillier, T Kucaba, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Pageof 36

Showing results (341-350 of 360) with videos related to

Sort By:
Pageof 36
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Science Translational Medicine|September 13, 2021
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxelChristina M Scribano, Jun Wan, Karla Esbona, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 17, 2025
Comparison of sample characteristics of Wisconsin Alzheimer's Disease Research Center participants with the Wisconsin state population-An evaluation of the recruitment effortYue Ma, Maria C Mora Pinzon, William R Buckingham, et al.
Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Science (New York, N.Y.)|January 8, 2021
A broadly protective antibody that targets the flavivirus NS1 proteinNaphak Modhiran, Hao Song, Lidong Liu, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|June 25, 2019
FLASHForward: plasma wakefield accelerator science for high-average-power applicationsR D'Arcy, A Aschikhin, S Bohlen, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
Nature Genetics|February 13, 1999
An encyclopedia of mouse genesM Marra, L Hillier, T Kucaba, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Pageof 36